Discussion
The execution of antimicrobial stewardship in private hospital environments reveals a pronounced divergence between clinician awareness and routine bedside practice. Healthcare professionals across multispecialty private institutions demonstrate broad recognition of the threat posed by drug-resistant pathogens; however, the absence of codified institutional policies and dedicated multidisciplinary teams frequently impairs structured execution [1], [6]. Empirical prescribing is often prioritized to avoid clinical deterioration in high-acuity wards, leading to excessive reliance on broad-spectrum agents without prompt microbiological confirmation. While medical practitioners frequently identify improper diagnostic utilization and irrational selection as primary drivers of resistance, institutional mechanisms rarely enforce pre-authorization or routine post-prescription reviews [6]. Consequently, clinical pharmacists and nursing personnel remain underutilized in monitoring treatment durations and therapy de-escalation [1]. Addressing this gap requires transitioning from voluntary guideline consultation to mandatory institutional oversight mechanisms that embed microbiological data directly into clinical decision-making pathways.